Policy uptake and implementation of the RTS,S/AS01 malaria vaccine in sub-Saharan African countries: status 2 years following the WHO recommendation
- PMID: 38688566
- PMCID: PMC11085798
- DOI: 10.1136/bmjgh-2023-014719
Policy uptake and implementation of the RTS,S/AS01 malaria vaccine in sub-Saharan African countries: status 2 years following the WHO recommendation
Abstract
In October 2021, the WHO recommended the world's first malaria vaccine-RTS,S/AS01-to prevent malaria in children living in areas with moderate-to-high transmission in sub-Saharan Africa (SSA). A second malaria vaccine, R21/Matrix-M, was recommended for use in October 2023 and added to the WHO list of prequalified vaccines in December 2023. This study analysis assessed the country status of implementation and delivery strategies for RTS,S/AS01 by searching websites for national malaria policies, guidelines and related documents. Direct contact with individuals working in malaria programmes was made to obtain documents not publicly available. 10 countries had documents with information relating to malaria vaccine implementation, 7 referencing RTS,S/AS01 and 3 (Burkina Faso, Kenya and Nigeria) referencing RTS,S/AS01 and R21/Matrix-M. Five other countries reported plans for malaria vaccine roll-out without specifying which vaccine. Ghana, Kenya and Malawi, which piloted RTS,S/AS01, have now integrated the vaccine into routine immunisation services. Cameroon and Burkina Faso are the first countries outside the pilot countries to incorporate the vaccine into national immunisation services. Uganda plans a phased RTS,S/AS01 introduction, while Guinea plans to first pilot RTS,S/AS01 in five districts. The RTS,S/AS01 schedule varied by country, with the first dose administered at 5 or 6 months in all countries but the fourth dose at either 18, 22 or 24 months. SSA countries have shown widespread interest in rolling out the malaria vaccine, the Global Alliance for Vaccines and Immunization having approved financial support for 20 of 30 countries which applied as of March 2024. Limited availability of RTS,S/AS01 means that some approved countries will not receive the required doses. Vaccine availability and equity must be addressed even as R21/Matrix-M becomes available.
Keywords: Child health; Malaria; Vaccines.
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Similar articles
-
Subnational introduction of the RTS,S/AS01E malaria vaccine into routine immunization: experience and lessons from the three pilot countries.Malar J. 2025 Jul 28;24(1):244. doi: 10.1186/s12936-025-05484-6. Malar J. 2025. PMID: 40721790 Free PMC article.
-
Feasibility, safety, and impact of the RTS,S/AS01E malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi.Lancet. 2024 Apr 27;403(10437):1660-1670. doi: 10.1016/S0140-6736(24)00004-7. Epub 2024 Apr 4. Lancet. 2024. PMID: 38583454 Free PMC article. Clinical Trial.
-
Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa.Malar J. 2011 Aug 4;10:224. doi: 10.1186/1475-2875-10-224. Malar J. 2011. PMID: 21816029 Free PMC article. Clinical Trial.
-
Current challenges and proposed solutions to the effective implementation of the RTS, S/AS01 Malaria Vaccine Program in sub-Saharan Africa: A systematic review.PLoS One. 2018 Dec 31;13(12):e0209744. doi: 10.1371/journal.pone.0209744. eCollection 2018. PLoS One. 2018. PMID: 30596732 Free PMC article.
-
[The RTS,S/AS01 malaria vaccine in children aged 5-17 months at first vaccination].Pan Afr Med J. 2018 Jun 19;30:142. doi: 10.11604/pamj.2018.30.142.13152. eCollection 2018. Pan Afr Med J. 2018. PMID: 30374388 Free PMC article. Review. French.
Cited by
-
Novel Nona-Repeat in Plasmodium ovale curtisi Circumsporozoite Protein Circulating in Cameroon.Curr Microbiol. 2025 Feb 7;82(3):125. doi: 10.1007/s00284-025-04106-3. Curr Microbiol. 2025. PMID: 39920482
-
Magnitude and durability of ProC6C-AlOH/Matrix-Mtm vaccine-induced malaria transmission-blocking antibodies in Burkinabe adults from a Phase 1 randomized trial.Hum Vaccin Immunother. 2025 Dec;21(1):2488075. doi: 10.1080/21645515.2025.2488075. Epub 2025 Apr 10. Hum Vaccin Immunother. 2025. PMID: 40208198 Free PMC article. Clinical Trial.
-
Mitigation of Malaria in Sub-Saharan Africa through Vaccination: A Budding Road Map for Global Malaria Eradication.Ethiop J Health Sci. 2025 May;35(3):205-217. doi: 10.4314/ejhs.v35i3.9. Ethiop J Health Sci. 2025. PMID: 40717722 Free PMC article. Review.
-
Current Developments in Malaria Vaccination: A Concise Review on Implementation, Challenges, and Future Directions.Clin Pharmacol. 2025 Apr 1;17:29-47. doi: 10.2147/CPAA.S513282. eCollection 2025. Clin Pharmacol. 2025. PMID: 40191019 Free PMC article. Review.
-
PfSPZ Vaccine induces focused humoral immune response in HIV positive and negative Tanzanian adults.EBioMedicine. 2024 Oct;108:105364. doi: 10.1016/j.ebiom.2024.105364. Epub 2024 Sep 30. EBioMedicine. 2024. PMID: 39353279 Free PMC article.
References
-
- WHO . World malaria report 2023. Geneva: World Health Organization; 2023.
-
- WHO: World Malaria Report . World malaria report 2022. Geneva: WHO; 2022.293.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials